Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd

Israeli study of all cause mortality in PsA vs general population ⭐️no increased mortality in PsA group ⭐️leading causes of death was cancer in both groups ⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs Abs#OP0219 #EULAR2021 @RheumNow

Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

Talk about unmet need. We must get better Rx for #Sogren’s Syndrome! Large survey show quality of life v poor in SS & correlates with degree of dryness in lacrimal & salivary glands POS0102 #EULAR2021 @eular_org @RheumNow

If we want drugs to be effective in #Sjogren’s Syndrome we need to see activity. The #Eular SS disease activity index ~ESSDAI in 511 SS pts found >50% w moderate to severe values BUT how much is Reversible ie fibro, fatigue, scarred glands? POS0105 @RheumNow @eular_org #EULAR2021

Disappointed to have missed lots of interesting sessions at Day 3 #EULAR2021 but look forward to catching up, starting with the difficult-to-treat #rheumatoidarthritis session! I particularly like this helpful summary on complexities & factors to consider in patients with D2T RA. https://t.co/H8n9Q2QNDW

Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7

What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well.. It’s time for more personalized approach to PsA treatment! Excellent talk by @DrLauraCoates Abs#OP6937 #EULAR2021 @RheumNow https://t.co/1NKLfmH2y5

Day 3 #EULAR2021 - A dose of #physicalactivity 🏃🏼 before conference to keep me sane with all interesting stuff presented https://t.co/jew2T9lnwB

Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY

Interesting small study on US assessment of Achilles of PsA vs normal pts after exercise ⭐️significant different of PD signal in PsA group ⭐️5 non-PsA pts still had PD🤔 Would be interesting to further classify differences in PD intensity… Abs#POS1058 #EULAR2021 @RheumNow https://t.co/SLhqq4wgCl

#Polypharmacy of meds not related to RA ⬇️remission & more adverse events but not if adjusting for comorbidities- so many diagnoses with RA ⬇️outcomes only defined as >1 drug #EULAR2021 @RheumNow OP0098 https://t.co/lMazBDTPw1

#OP0224 Estimating clinical meaningful threshold for disease activity and improvement in composite measures of disease activity in 139 PsA patients over 3 clinical visits. Usefulness for clinics and further testing in different settings warranted @RheumNow #EULAR2021 https://t.co/mwHJwIhRVE